SCB-2022B

N/A

Report date: 2025/01/26 17:58:09

Base Information

Drug NameSCB-2022B
Drug Alias Namemonovalent omicron variant vaccine (Clover Biopharmaceuticals)SCB-2022B
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine
Mechanisms of ActionCoronavirus spike glycoprotein modulators
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesClover Biopharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesClover Biopharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A